DDInter375 DDInter915
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Ciclesonide {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Ciclesonide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Ciclesonide {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Ciclesonide {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is associated with {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Ciclesonide {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Ciclesonide {u} (Compound) resembles {v} (Compound) Budesonide
Budesonide {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Ciclesonide {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Ciclesonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Ciclesonide {u} (Compound) resembles {v} (Compound) Budesonide
Budesonide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Ciclesonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Ciclesonide (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Ciclesonide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Ciclesonide (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Indacaterol (Compound)
Ciclesonide (Compound) treats asthma (Disease) and asthma (Disease) is associated with ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)
Ciclesonide (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Ciclesonide (Compound) resembles Budesonide (Compound) and Budesonide (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Ciclesonide (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Ciclesonide (Compound) resembles Budesonide (Compound) and Budesonide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)